Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportClinical PET

FAPI: Still more question to be answered-A review based analysis

Madhusudan Vyas and Angus Glassenbury
Journal of Nuclear Medicine June 2023, 64 (supplement 1) T55;
Madhusudan Vyas
1Unitec Institute of Technology and Mercy radiology, Auckland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angus Glassenbury
2Mercy Radiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

T55

Introduction: Over ninety percent of epithelial malignancies have elevated levels of fibroblast activation protein (FAP), a type II transmembrane serine protease that is closely associated with tumour invasion, metastasis, and prognosis. Using FAP as a target, different FAP inhibitors (FAPIs) have been developed; the majority of these FAPIs have nanomolar levels of FAP affinity and high selectivity, and they are used for positron emission tomography (PET) imaging of diverse cancers. FAPIs are projected to be the new molecule of the century with greater imaging effects than 18F-FDG in a number of diseases, such as gastrointestinal tumours, liver tumours, breast tumours, and nasopharyngeal carcinoma, based on current research. FAPIs are a complementing molecular imaging method to 18F-FDG. Current paper present the review of currebntly published litreature in terms of FAPI and its clinical role in oncology.

Methods: The author did a thorough review of all the articles and clinical trials that came out in the last three years, using databases like PubMed, Medline, and EBSCO. All of the literature that was looked at was summed up and evaluated so that the role of FDG and other receptor-based imaging techniques (PSMA and DOTA) could be compared with the role of FAPI only imaging. The real question was whether FAPI imaging alone is the answer to everything or whether we still need other approved imaging before FAPI imaging.

Results: The reviewed literature demonstrated a trend towards discordant imaging rather than FAPI alone, since the biological changes and an increase in FAPI have not been able to fix the obvious problems. In order to properly plan treatment for patients, conventional imaging, which may include FDG, PSMA, or DOTA, is still essential. This is because each of these procedures is a uniquely customised diagnostic test that is necessary..

Conclusions: The reviewed literature suggests that further research has to be conducted before FAPI-based PET imaging may be used as a primary scanning approach since there are still many questions that have not been resolved.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 64, Issue supplement 1
June 1, 2023
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FAPI: Still more question to be answered-A review based analysis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
FAPI: Still more question to be answered-A review based analysis
Madhusudan Vyas, Angus Glassenbury
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) T55;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
FAPI: Still more question to be answered-A review based analysis
Madhusudan Vyas, Angus Glassenbury
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) T55;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Title Non-prostate diseases seen on PSMA PET imaging.
  • Dose Optimization in PET/CT: Minimizing F-18 FDG Dose for Improved Safety, Efficiency, and Efficacy
  • Dynamic 18F-Fluorothymidine PET imaging of metastatic lesions post-radiotherapy to differentiate tumour progression from radionecrosis
Show more Clinical PET

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire